<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033241</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-774-155</org_study_id>
    <secondary_id>CDR0000069266</secondary_id>
    <secondary_id>UARIZ-HSC-01128</secondary_id>
    <secondary_id>NCI-V02-1694</secondary_id>
    <nct_id>NCT00033241</nct_id>
  </id_info>
  <brief_title>Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors</brief_title>
  <official_title>A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially Responsive Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the&#xD;
      tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining erlotinib with gemcitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining erlotinib with gemcitabine in&#xD;
      treating patients who have newly diagnosed locally advanced or metastatic pancreatic cancer&#xD;
      or other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of erlotinib in combination with gemcitabine in&#xD;
           patients with recently diagnosed, gemcitabine-naive, locally advanced or metastatic&#xD;
           pancreatic carcinoma or other potentially responsive solid tumor.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the objective antitumor response rate and response duration in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the time to disease progression and duration of overall survival in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of erlotinib.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30 minutes on day 1 of weeks 1-7 and oral erlotinib once&#xD;
      daily beginning on day 3 of week 1 and continuing for 8 weeks (course 1). Patients receive&#xD;
      subsequent courses of therapy comprising gemcitabine once weekly for 3 weeks and erlotinib&#xD;
      once daily. Courses repeat every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 12 additional&#xD;
      patients are accrued and treated at the MTD as above.&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2001</start_date>
  <completion_date type="Actual">April 22, 2004</completion_date>
  <primary_completion_date type="Actual">April 22, 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Pancreatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced or metastatic epithelial&#xD;
             carcinoma of the pancreas or other malignancy considered to be potentially responsive&#xD;
             to gemcitabine&#xD;
&#xD;
               -  Newly diagnosed or gemcitabine naive&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Not amenable to surgical intervention due to medical contraindications or&#xD;
             non-resectability of the tumor&#xD;
&#xD;
          -  No islet cell tumors or other non-epithelial cell carcinomas of the pancreas&#xD;
&#xD;
          -  No active CNS metastases or leptomeningeal disease&#xD;
&#xD;
               -  Treated or asymptomatic brain metastases are allowed if on a stable dose of&#xD;
                  corticosteroids and/or there is no change in brain disease status for at least 4&#xD;
                  weeks after related therapy (e.g., whole-brain radiotherapy)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (except for documented Gilbert's syndrome)&#xD;
&#xD;
          -  AST or ALT less than 2 times upper limit of normal (ULN) (no greater than 5 times ULN&#xD;
             if hepatic obstruction or metastases present)&#xD;
&#xD;
          -  Albumin at least 2.5 g/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No history of congestive heart failure currently requiring therapy&#xD;
&#xD;
          -  No ventricular arrhythmia requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  No severe conduction disturbances&#xD;
&#xD;
          -  No angina pectoris requiring therapy&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No significant gastrointestinal abnormalities including:&#xD;
&#xD;
               -  Requirement for IV alimentation&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          -  No significant ophthalmologic abnormalities including:&#xD;
&#xD;
               -  Severe dry eye syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Severe exposure keratopathy&#xD;
&#xD;
               -  Disorders that would increase the risk for epithelium-related complications&#xD;
                  (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic&#xD;
                  keratitis)&#xD;
&#xD;
               -  Abnormal Schirmer test (less than 2 mm) allowed provided there is no evidence of&#xD;
                  clinically significant corneal surface abnormalities&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known or suspected hypersensitivity to gemcitabine&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except treated non-melanoma skin cancer or&#xD;
             carcinoma in situ of the breast or cervix&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No psychiatric disorders or altered mental status the would preclude informed consent&#xD;
             or study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 28 days since prior immunotherapy or biological response modified therapy for&#xD;
             the primary malignancy&#xD;
&#xD;
          -  No concurrent immunotherapy or biologic response modifier therapy for the primary&#xD;
             malignancy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy for the primary malignancy&#xD;
&#xD;
          -  No prior mitomycin or nitrosoureas for the primary malignancy&#xD;
&#xD;
          -  No more than 6 prior courses of chemotherapy with an alkylating agent for the primary&#xD;
             malignancy&#xD;
&#xD;
          -  No prior gemcitabine for the primary malignancy except as a low-dose (less than 500&#xD;
             mg/m^2) radiosensitizer administered concurrently with or within 2 weeks after&#xD;
             radiotherapy at least 3 months ago&#xD;
&#xD;
          -  No other concurrent chemotherapy for the primary malignancy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior systemic hormonal therapy (except LH-RH agonists) for the&#xD;
             primary malignancy&#xD;
&#xD;
          -  No concurrent systemic hormonal therapy (except LH-RH agonists) for the primary&#xD;
             malignancy&#xD;
&#xD;
          -  Other concurrent endocrine therapy is allowed as follows:&#xD;
&#xD;
               -  Hormonal therapy (e.g., megestrol) for appetite stimulation&#xD;
&#xD;
               -  Nasal, ophthalmic, or topical glucocorticoids&#xD;
&#xD;
               -  Oral glucocorticoids for adrenal insufficiency&#xD;
&#xD;
               -  Low-dose maintenance steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy for the primary malignancy or metastases and&#xD;
             recovered&#xD;
&#xD;
          -  No prior wide-field radiotherapy to 25% or more of marrow-bearing bone&#xD;
&#xD;
          -  No prior pelvic irradiation&#xD;
&#xD;
          -  No concurrent radiotherapy for the primary malignancy or metastases&#xD;
&#xD;
          -  No concurrent wide-field radiotherapy for pain management&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from any prior surgery&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior agent for the primary malignancy targeting the epidermal growth factor&#xD;
             receptor (EGFR) or EGFR-specific tyrosine kinase activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Santabarbara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OSI Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3271</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=61</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <results_reference>
    <citation>Dragovich T, Patnaik A, Rowinsky EK, et al.: A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-895, 2003.</citation>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

